Share Name Share Symbol Market Type Share ISIN Share Description
Crh Plc LSE:CRH London Ordinary Share IE0001827041 ORD EUR 0.32
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -0.03% 2,890.00 2,889.00 2,891.00 2,910.00 2,865.00 2,873.00 65,002 08:56:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Construction & Materials 21,265.1 1,789.8 203.7 13.4 22,681

Crh Share Discussion Threads

Showing 326 to 347 of 350 messages
Chat Pages: 14  13  12  11  10  9  8  7  6  5  4  3  Older
Given covid-19 problems, this looks like a very good recovery play that will benefit from post-Coronavirus stimulus (and not a lot will know this, as this thread isn't much read, lol).
should be selling quite a few shop windows in America!
debt reduction and the ongoing buyback I believe, with some small acquisitions. the company has a big cost cutting program which should increase margins by 3% if they follow through successfully
A lot of RNS's to wade through with the buyback. Does anyone know off the top what the plan was for the proceed's from the sale of Europe distribution business? I've had these for a while and I'm in a small profit and some divi's thrown in along the way. Wondering if the plans are for a return of cash to holders, investment in growth, debt reduction, BOD's Xmas party etc.?
wet your knot
Please see SKIN - about to move up. 1) Laboratory grown human skin that can be tested on, instead of testing on animals 2) Only commercially available option of its type. 3) Exploiting high growth technologies such as Artificial Intelligence 4) Human skin cloning duplicates test subjects 5) It is an Ethical investment 6) Exploiting CBD market 7) Cutting edge Woundcare -Visual diagnostic wound dressing that changes colour to indicate infection or improvement of the wound under the dressing. 8) Expanding laboratory space by 100% to accommodate the rate of growth due to be RNS any day 9) Currently negotiating further contracts. (8 CBD we know of and others) due to be RNS soon 10) Fully funded - The growth of the Company has been so well supported and received by the market that all corporate activity has been achieved, funding in place to accommodate the continued growth. 11) Meeting its objective of increasing the average revenue per client as it evolves into a multiple revenue stream product and services company 12) Four Blue-Chip (US and EU) client agreements signed 13) owns 9.35% of Cellulac plc 14) Algzym - A patented enzyme-based technology which bursts algal cell walls and releases Omega 3 oils in a simple solvent-free process. 15) Company moving forward at a rapid pace. 16) Major relationships already built with billion-dollar companies 17) Sales routes for products already in place in multiple countries 18) EU laws changing to force companies to stop beauty and pharmaceuticals testing on animals. 19) EU laws changing to force companies to stop making claims they can't back up scientifically. 20) EU laws changing to force companies to comply with more rigorous testing before market launch. 21) Presenting at major US and European Skin and Dermatology events 22) Presenting at major CBD Exhibitions 23) Strong, dynamic and driven board 24) CEO is an owner of company/major investor The chart is primed for a great entry' hTTps://
Buying more now.
A very inactive chat room. If anyone reads this post can you give it a like or dislike?
Quiet board
CRH News Out Just Now
The sleeping giant awakens
CRH........CRH PLC trading update yesterday bullish on second half. Good write up here......... One Footsie dividend growth stock I’d buy and one I’d sell today Rupert Hargreaves | Wednesday, 25th April, 2018 Building materials company CRH (LSE: CRH) might not look like a traditional income stock at first glance, but current City forecasts suggest this business is going to grow into one over the next few years. Indeed according to City figures, over the next two years CRH’s dividend payout to investors is expected to grow by around 10% to €0.75 per share by 2019. But to me, this looks like a conservative forecast given CRH’s management has always prioritised investor returns. For example, the firm announced today a €1bn share buyback to return additional capital, even though trading during the first quarter has been mixed. Thanks to “prolonged winter weather conditions and the timing of Easter holidays” first quarter like-for-like sales declined 2%. Group earnings before interest tax depreciation and amortisation (EBITDA) are expected to be in line with last year’s print. Nevertheless, after this minor setback, management is expecting EBITDA to be ahead of last year in the second half “in the absence of any major market dislocations,” according to its trading update issued today for the three months ended 31 March. Improving the portfolio CRH’s management is always on the lookout for ways to improve performance. Thanks to these efforts, earnings per share have more than doubled over the past six years. And it doesn’t look as if the enterprise is going to slow down anytime soon. During the first quarter, the company spent €150m on six bolt-on acquisitions and is planning €1.5bn-€2bn for further portfolio divestments over the “medium term” as the group tries to streamline its portfolio and improve overall returns. While some of this divestment cash will be returned to investors, I believe some will also be invested in new growth opportunities. Analysts have pencilled in earnings per share growth of 24% of 2018, followed by 15% for 2019. Based on these estimates, the shares are trading at a 2019 P/E of 12.6, which looks to me to be too cheap considering CRH’s historical growth and income potential. The shares currently support a dividend yield of 2.6%. ============================================================================= I agree with the tipster the stock looks very cheap given EPS growth going forward. Analysts have pencilled in earnings per share growth of 24% of 2018, followed by 15% for 2019 Never mind an income stock those figures equate to a ZULU stock under the late Jim Slaters formula.
3rd eye
Ash Grove seems a good strategic fit.
CRH sales climb as building group enjoys a 'Trump bounce' HTTP://
2016 – The Great Irish Share Valuation Project (Part II): Company: CRH (CRH:ID) Last TGISVP Post: Here Market Cap: EUR 22,579 M Price: EUR 27.40 When Albert Manifold kicked off as CEO, it certainly looked like he was planning to right-size a rather stretched balance sheet (I even wondered whether he’d launch a rights issue). But it’s always hugely tempting for a new CEO (esp. the CEO of an Irish corporate icon like CRH), to make his mark as an empire-builder, so that resolve didn’t last long… Despite announcing a €1.5-2.0 billion multi-year disposal programme in late-2014, 2015 proved to be the year for mega-acquisitions – totaling almost €8 billion, primarily the Lafarge-Holcim & C.R. Laurence Co acquisitions. [OK, Manifold did a placing in the end, but only to fund about 25% of the LH deal]. While underlying organic growth’s now progressing at a very healthy clip (primarily driven by renewed US momentum), we haven’t reached a point where it’s easy to determine an appropriate P/E multiple – therefore, we’ll use a similar approach to my previous write-up. Noting CRH’s two big acquisitions closed in H2-2015, first we need to calculate a post-acquisition revenue run-rate: LH revenue’s €5.1 billion & the deal closed end-July, so that’s a €3.0 billion revenue bump for FY-2016. And CRL revenue’s $570 million & it closed end-Aug – an additional $380 million revenue bump. CRH’s FY-2015 EBIT margin was 5.6%, which compares to a peak 9.9% margin (back in 2007) – so relying on the company’s actual Op FCF margin (of 8.3%) seems appropriate here for valuation purposes & deserves a 0.75 P/S multiple. [Which seems fair for the incremental acquisition revenue also – LH & CRL earn much higher EBITDA margins than CRH, but since CRH’s Op FCF margin’s about 50% higher than its EBIT margin, it seems unwise to specifically adjust margin higher for these acquisitions]. And looking at average FY-2015 debt levels vs. year-end debt of €9.2 billion vs. underlying net interest costs, I estimate FY-2016 net interest cost will be around €366 million (vs. a prior €295 million), which is just over 16% of Op FCF – so a debt adjustment no longer seems necessary, bearing in mind CRH also has €2.5 billion cash on hand (also provides cover for a €0.6 billion pension deficit). [OK, props to Manifold…he217;s bloody well cashing his way out of a stretched balance sheet!]: (EUR 23.6 B Rev + 3.0 B LH + $0.4 B CRL / 1.1115 EUR/USD) * 0.75 P/S / 824 M Shares = EUR 24.53 CRH looks marginally over-valued at this point. But noting the underlying momentum of its US business, and likely cost savings to come from its two major acquisitions, we should hopefully see it grow into its current market cap over the next year. But investors should also be mindful of potential integration and/or (renewed) economic risks here, which could prove challenging for a company that’s relatively leveraged at this point. Price Target: EUR 24.53 Upside/(Downside): (10)% — For related links/graphs/files, and more TGISVP analyses/price targets: Google the Wexboy investment blog.
Very quiet over here. 18.00 seem to be a very strong support,a very strong rebound today, I hope now rise between 10-20% Let see
Good move today, the only way is up
Can't believe they sold UK clay products like Ibstock in UK. A fine company that I know well personally. It will go from strength to strength. I appreciate it is only a small fish in a large ocean to them however of which currently does not have the RONA of its other companies.
this is a massive acquisition.
CRH #CRH will spend €6.5bn on assets from Holcim and Lafarge. As mentioned on today's ADVFN podcast>
CRH is featured in today's ADVFN podcast To listen click here> In today's podcast: - City Investor and financial write Chris Oil will be chatting about a small cap oil stock that city analysts reckon could be a ten bagger. Chris on Twitter is @ChrisOil - And the micro and macro news including: Tesco #TSCO Quindell #QPP Ted Baker #TED Standard Chartered #STAN Spirent Communications #SPT Howden Joinery #HWDN Marks and Spencer #MKS CRH #CRH Hays #HAS Talk Talk #TALK British Land #BLND Grafton #GFTU Dunelm Group #DNLM Samsung SQS Software #SQS Renishaw #RSW Zoopla #ZPLA #BOO Foxtons Group #FOXT Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below. Ten Bagger Tuesday (All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below: Suggest a stock (Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). You can subscribe to this podcast in iTunes by clicking HERE To follow me on Twitter click HERE As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions: Bronze - £50 (normally £73.82/year) Silver - £145 (normally £173.71/year) Level 2 - £350 (normally £472.94/year) Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just CLICK HERE for more information. Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing. Justin    
Good entry point?
Company: CRH Prior Post(s): 2012 & 2013 Ticker: CRH:ID Price: EUR 20.98 2013 wasn't a great year for CRH – the new CEO, Albert Manifold, has inherited an uphill task (& a stretched balance sheet) from veteran Myles Lee. Total revenue fell marginally – again, weak trading in Europe was the culprit, but it's notable CRH's (2012) US momentum has mostly dissipated (with revenue up just 2%). Europe had a more pronounced (negative) impact on profitability, with CRH's underlying operating profit margin falling to just 4.0%. [This performance also prompted a 2013 portfolio review, resulting in a EUR 0.6 billion write-down & a plan to divest 45 (primarily European) business units]. Fortunately, this kind of stagnation often benefits the cash flow statement – something we can reasonably expect again in 2014 – for 2013, this resulted in a 5.6% operating free cash flow (Op FCF) margin. For valuation purposes, I'll still assume we'll see an eventual convergence towards CRH's long-term margins of almost 10% – so let's utilize an average 7.8% margin here. However, it's worth highlighting fresh anxieties over Chinese/emerging market growth mean the timing of this convergence has become that much more uncertain... On the other hand, CRH is still the Irish blue chip for domestic & international investors (well, even though it's not very Irish...) – so I'll continue to assign a 0.7 P/S multiple. But leverage remains a big problem – EUR 255 million of net interest expense is a whopping 35% of adjusted operating profit. But let's be generous here & focus on CRH's Op FCF of just over EUR 1.0 B instead...unfortunately, net interest's still over 25% of this figure. I calculate total debt (of 5.5 B) would need to be reduced by about 39%, to limit net interest to 15% of Op FCF – therefore, we'll include a 2.1 B (negative) debt adjustment in our valuation, plus a 336 M adjustment for the net pension deficit. However, cash has now accumulated to a rather ridiculous 2.5 B – I suspect management will opt for ample liquidity, but it seems reasonable to assume 50% of this cash will be used to offset debt balances/maturities. Put all this together & we have: (EUR 18.0 B Revenue * 0.7 P/S + 2.5 B Cash * 50% – 2.1 B Debt Adjustment – 0.3 B Net Pension Deficit) / 735 M Shares = EUR 15.53 CRH remains pretty over-valued. I suspect there's a potential takeover premium embedded in the price – considering the Holcim-Lafarge merger news, we may be on the verge of a new wave of consolidation. If that's the case, CRH is a mere morsel – shareholders often seem to presume it's a global player, but in reality it barely cracks the top 40 largest cement companies. Meanwhile, shareholders probably face another tough year...and it might prove tempting for the new CEO to indulge in another kitchen-sink job this year, or to even consider a rights issue. Price Target: EUR 15.53 Upside/(Downside): (26)%
Chat Pages: 14  13  12  11  10  9  8  7  6  5  4  3  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200708 08:11:33